# US 2026/0284102 A1 · Pharmaceutical composition for preventing or treating sepsis containing functionalized transition metal dichalcogenide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0284102 A1
- Document ID: US20260284102A1
- Status: Published application
- Kind: A1
- Application number: 19/694,556
- Filed: 2026-06-01
- Published: 2026-09-24
- Earliest claimed: 2020-06-25
- Assignees: Industry-University Cooperation Foundation Hanyang University Erica Campus
- Applicants: Industry-University Cooperation Foundation Hanyang University Erica Campus
- Inventors: Jong-Ho Kim; Chul-Su Yang; DaBin Yim
- Web page: https://patentgrep.com/patent/US20260284102A1

## CPC

- A61K 31/765: Polymers containing oxygen
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/70: Web, sheet or filament bases {; Films; Fibres of the matrix type containing drug (hollow drug-filled fibres A61K9/0092)}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 47/02: Inorganic compounds
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 39/06: Free radical scavengers or antioxidants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A 2D TMD nanosheet functionalized with an amphiphilic block polymer compound of the present disclosure has scavenging activity for intracellular and mitochondrial ROS and the scavenging activity is maintained well at low pH, and further, inhibits the excessively increased secretion of inflammatory cytokines in microbial infection, exhibits antibacterial activity, and can increase survivability and prevent aggravation of symptoms in an animal model of sepsis, it can be provided as an anti-inflammatory/antioxidant agent for prevention and treatment of sepsis and septic shock.

## Claims

### Claim 1

A method for preventing or treating sepsis or septic shock, comprising a step of administering a 2D transition metal dichalcogenide (TMD) functionalized with an amphiphilic block polymer compound comprising a hydrophilic block and a hydrophobic block to a subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the hydrophilic block is polyethylene glycol (PEG).

### Claim 3 (depends on 1)

The method of claim 1, wherein the hydrophobic block is poly(ε-caprolactone) (PCL).

### Claim 4 (depends on 1)

The method of claim 1, wherein the amphiphilic block polymer compound comprises PEG and PCL and has a structure of Chemical Formula 1:
wherein n is an integer from 400 to 3000.

### Claim 5 (depends on 1)

The method of claim 1, wherein the TMD is one or more selected from a group consisting of tungsten disulfide (WS2), molybdenum diselenide (MoSe2) and tungsten diselenide (WSe2).

### Claim 6 (depends on 1)

The method of claim 1, wherein the functionalized 2D TMD has a thickness of 1-50 nm.

### Claim 7 (depends on 1)

The method of claim 1, wherein the functionalized 2D TMD has a lateral length of 1-500 nm.

### Claim 8 (depends on 1)

The method of claim 1, wherein the functionalized 2D TMD has the activity of scavenging intracellular and/or mitochondrial ROS and/or RNS.

### Claim 9 (depends on 1)

The method of claim 1, wherein the functionalized 2D TMD inhibits the secretion of an inflammatory cytokine.

### Claim 10 (depends on 9)

The method of claim 9, wherein the inflammatory cytokine is TNF-α, IL-1β, IL-6, IL-18 or IL-12p40.

### Claim 11 (depends on 1)

The method of claim 1, wherein the administration is intravenous administration or intraperitoneal administration.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is a mammal exhibiting acute inflammatory response to microbial infection.
